NCT00835549View on ClinicalTrials.gov

Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Healthy
Interventions
DRUG

Cefdinir for oral suspension 250 mg/5mL

1 x 250 mg/5mL, single-dose non-fasting

DRUG

OMNICEF® for oral suspension 250 mg/5mL

1 x 250 mg/5mL, single-dose non-fasting

Trial Locations (2)

77042

Novum Pharmaceutical Research Services, Houston

77099

Bioassay Laboratory, Inc., Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00835549 - Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting | Biotech Hunter | Biotech Hunter